stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. SRZN
    stockgist
    HomeTop MoversCompaniesConcepts
    SRZN logo

    Surrozen, Inc.

    SRZN
    NASDAQ
    Healthcare
    Biotechnology
    South San Francisco, CA, US40 employeessurrozen.com
    $27.82
    -0.62(-2.19%)

    Mkt Cap $208M

    $6.50
    $29.13

    52-Week Range

    At a Glance

    AI-generated

    Revenue breakdown: Collaboration And License Revenue (93.7%), Research Service Revenue (6.3%).

    8-K
    Surrozen, Inc. announced fourth quarter and full year 2025 financial results, reporting a full year net loss of $242.0 million or ($32.37) per share compared to $63.6 million or ($21.67) per share in 2024, driven by non-cash losses on PIPE transactions. Cash and equivalents were $89.2 million as of December 31, 2025, with pipeline progress including a planned IND submission for SZN-8141 in H2 2026.

    $208M

    Market Cap

    $4M

    Revenue

    —

    Net Income

    Employees40
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Collaboration And License Revenue93.7%($20M)
    Research Service Revenue6.3%($1M)

    Revenue by Geography

    DE93.5%($10M)
    US6.5%($700.0K)
    Activity

    What Changed Recently

    Management Change
    Jan 29, 2026

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Resignati

    Financial Results
    Mar 22, 2026

    . Results of Operations and Financial Condition” (including the exhibit referenced herein) shall not be deemed to be “filed” for the purposes of Section 18 of t

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    IMMXImmix Biopharma, Inc.$8.91+3.36%$472M-11.9
    IRDOpus Genetics, Inc.$4.55-2.99%$324M-57.6
    GLSIGreenwich LifeSciences, I...$22.70-1.13%$314M-17.7
    AGENAgenus Inc.$3.33-1.91%$128M1133.3
    SEERSeer, Inc.$1.71+0.29%$96M-1.3
    CGTXCognition Therapeutics, I...$0.88-1.84%$64M-3.1
    TILInstil Bio, Inc.$7.94-1.12%$54M-0.8
    ATOSAtossa Therapeutics, Inc.$5.37+5.09%$46M-1.6
    Analyst View
    Company Profile
    CIK0001824893
    ISINUS86889P2083
    CUSIP86889P109
    Phone650 489 9000
    Address171 Oyster Point Boulevard, South San Francisco, CA, 94080, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice